SpringerLink
Log in

Topical Therapies for Nonmelanoma Skin Cancers

  • Chapter
  • First Online:
Skin Cancer Management

  • 505 Accesses

Abstract

As the incidence of nonmelanoma skin cancer (NMSC) continues to rise, topical therapies may be used with increasing frequency. Topical therapies are currently being utilized mainly as primary or adjunctive means of treating NMSC. Although surgical therapies, such as Mohs micrographic surgery (MMS), remain the mainstay for tumor removal, topical therapy can provide an alternative treatment modality for some skin cancer patients as well as serving as a useful adjunct to surgery. Topical therapies may also increase overall efficacy in the management of subclinical lesions and identifying asymmetrical growth of NMSCs. In some patients, such as high-risk surgical candidates, they may be used to avoid or to minimize the extent of surgery. Topical therapies may also be helpful in a diagnostic manner. In instances where biopsy sites are equivocal, topical therapies may facilitate tumor identification prior to surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Desai T, Chen CL, Desai A, et al. Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon. Dermatol Surg. 2012;38:97–103.

    CAS  PubMed  Google Scholar 

  2. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27(2):190–9.

    CAS  PubMed  Google Scholar 

  3. Barnetson RC, Satchell A, Zhuang L, et al. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol. 2007;29:639–43.

    Google Scholar 

  4. Wolf IH, Kodama K, Cerroni L, et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007;29(3):237–41.

    PubMed  Google Scholar 

  5. Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204(6):1441–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Wolverton SE. Comprehensive dermatologic drug therapy. 3rd ed. Philadelphia: Saunders Elsevier; 2012.

    Google Scholar 

  7. Medonca CO, Yates VM. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol. 2006;31:721.

    Google Scholar 

  8. Al-Dujaili Z, Hsu S. Imiquimod-induced vitiligo. Dermatol Online J. 2007;13(2):10.

    PubMed  Google Scholar 

  9. Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52(4):715–6.

    PubMed  Google Scholar 

  10. Senel E, Seckin D. Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol. 2007;73(6):423.

    PubMed  Google Scholar 

  11. Stefanki C, Nicolaidu E, Hadjivassilou M, et al. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol. 2006;20(6):755–6.

    Google Scholar 

  12. Campagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol. 2003;109:224–7.

    CAS  PubMed  Google Scholar 

  13. Chakrabarty AK, Mraz S, Geisse JK, et al. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol. 2005;52(2 Suppl 1):35–7.

    PubMed  Google Scholar 

  14. Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140(7):889–90.

    PubMed  Google Scholar 

  15. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol. 2005;141(7):908–9.

    PubMed  Google Scholar 

  16. Marty CL, Randle HW, Walsh JS. Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatol Surg. 2005;31(7 Pt 1):780–3.

    CAS  PubMed  Google Scholar 

  17. McQuillan O, Higgins SP. Acute urinary retention following self-treatment of genital warts with imiquimod 5% cream. Sex Transm Infect. 2004;80(5):419–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Fanti PA, Dika E, Vaccari S, et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol. 2006;45(12):1464–5.

    CAS  PubMed  Google Scholar 

  19. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140(12):1490–5.

    CAS  PubMed  Google Scholar 

  20. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol. 2006;31(1):140–1.

    CAS  PubMed  Google Scholar 

  21. Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol. 2004;45(2):123–4.

    PubMed  Google Scholar 

  22. Taylor CL, Maslen M, Kapembwa M. A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect. 2006;82(3):227–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118(1223):1–4.

    Google Scholar 

  24. Patel VM, Schwartz RA, Lambert CL. Safety of topical medications in pregnancy. J Drugs Dermatol. 2016;15(7):830–4.

    CAS  PubMed  Google Scholar 

  25. Farrar CW, Bell HK, King CM. Allergic contact dermatitis from propylene glycol in Efudix®. Contact Dermatitis. 2003;48:345.

    CAS  PubMed  Google Scholar 

  26. Meijer BUGA, de Waard-van der Spek FB. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix® cream). Contact Dermatitis. 2007;57:58–60.

    Google Scholar 

  27. Johnson MR, Hageboutros A, Wang K, et al. Life threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006–11.

    CAS  PubMed  Google Scholar 

  28. Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDS). Br J Dermatol. 2007;156(Suppl 3):25–33.

    CAS  PubMed  Google Scholar 

  29. Kerr OA, Kavanagh G, Horn H. Allergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2002;47(3):175.

    CAS  PubMed  Google Scholar 

  30. Kleyn CE, Bharati A, King CM. Contact dermatitis from 3 different allergens in Solaraze® gel. Contact Dermatitis. 2004;51(4):215–6.

    CAS  PubMed  Google Scholar 

  31. Kowalzick L, Ziegler H. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2006;54(6):348–9.

    CAS  PubMed  Google Scholar 

  32. Lebwohl M, Shumack S, Gold LS, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.

    CAS  PubMed  Google Scholar 

  33. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.

    CAS  PubMed  Google Scholar 

  34. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486–93.

    CAS  PubMed  Google Scholar 

  35. Amini S, Viera MH, Valins W, et al. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:20–34.

    PubMed  PubMed Central  Google Scholar 

  36. Fallen R, Gooderham M. Ingenol mebutate: an introduction. Skin Therapy Lett. 2012;17:1–3.

    PubMed  Google Scholar 

  37. Dosik JS, Damstra M, Udell C, et al. Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate in healthy volunteers. J Clin Aesthet Dermatol. 2014;7(4):35–42.

    PubMed  PubMed Central  Google Scholar 

  38. Fidler B, Goldberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. Pharm Ther. 2014;39(1):40–6.

    Google Scholar 

  39. Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol. 2007;57(3):484–502.

    PubMed  Google Scholar 

  40. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–41.

    CAS  PubMed  Google Scholar 

  41. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle controlled, double blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57(2):265–8.

    PubMed  Google Scholar 

  42. Hadley G, Derry S, Moore R. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251–5.

    CAS  PubMed  Google Scholar 

  43. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis. Arch Dermatol. 2005;141:467–73.

    CAS  PubMed  Google Scholar 

  44. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50(5):714–21.

    PubMed  Google Scholar 

  45. Persuad AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol. 2002;47(4):553–6.

    Google Scholar 

  46. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47(4):571–7.

    PubMed  Google Scholar 

  47. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498–502.

    CAS  PubMed  Google Scholar 

  48. Szeimes R, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547–55.

    Google Scholar 

  49. Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett. 2001;6(9):1–4.

    CAS  PubMed  Google Scholar 

  50. Jury CS, Ramraka-Jones VS, Gudi V, et al. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol. 2005;153(4):808–10.

    CAS  PubMed  Google Scholar 

  51. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990–1000.

    CAS  PubMed  Google Scholar 

  52. Robbins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol. 2002;1:25–30.

    Google Scholar 

  53. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1,2, or 4 weeks. Cutis. 2002;70(Suppl 2):22–9.

    PubMed  Google Scholar 

  54. Fariba I, Ali A, Hossein SA, et al. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol. 2006;72(5):346–9.

    PubMed  Google Scholar 

  55. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44(1):40–3.

    PubMed  Google Scholar 

  56. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3(4):401–7.

    PubMed  Google Scholar 

  57. Pirard D, Vereecken P, Melot C, et al. Three percent diclofenac in 2.5% hyaluron gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005;297(5):185–9.

    CAS  PubMed  Google Scholar 

  58. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94–100.

    CAS  PubMed  Google Scholar 

  59. Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17(3):173–9.

    CAS  PubMed  Google Scholar 

  60. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934–43.

    PubMed  Google Scholar 

  61. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle- controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.

    PubMed  Google Scholar 

  62. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39–48.

    CAS  PubMed  Google Scholar 

  63. Krawthcenko N, Roewert-Huber J, Ulrich M, et al. A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1 year follow up. Br J Dermatol. 2007;157(Suppl 2):34–40.

    Google Scholar 

  64. Tanghetti E, Werschler WP. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6(2):144–7.

    PubMed  Google Scholar 

  65. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9(5):209–14.

    PubMed  Google Scholar 

  66. Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus imiquimod for the treatment of actinic keratosis. J Am Acad Dermatol. 2018;78(4):710–6.

    CAS  PubMed  Google Scholar 

  67. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007;6(8):778–81.

    PubMed  Google Scholar 

  68. Demehri S, Turkoz A, Manivasagam S, et al. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell. 2012;22(4):494–505.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Ito K, Koga M, Shibayama Y, et al. Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis. J Dermatol. 2016;43(4):402–5.

    CAS  PubMed  Google Scholar 

  70. Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106–16.

    PubMed  Google Scholar 

  71. Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(6):965.e1–12.

    CAS  PubMed  Google Scholar 

  72. Seckin D, Cerman AA, Yildiz A, et al. Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report. J Drugs Dermatol. 2009;8(5):451–4.

    PubMed  Google Scholar 

  73. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140(7):813–6.

    CAS  PubMed  Google Scholar 

  74. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5(2):133–9.

    CAS  PubMed  Google Scholar 

  75. Berlin J, Rigel D. A prospective double-arm, multicenter, open-label phase IV evaluation of the use of diclofenac sodium 3% gel in the treatment of AK lesions post-cryosurgery. J Am Acad Dermatol. 2007;56(2):AB147. P2303 poster presentation.

    Google Scholar 

  76. Pasquali P, Sequrado-Miravalles G, Gonzalez S. Sequential treatment of actinic keratosis with cryotherapy and ingenol mebutate: reflectance confocal microscopy monitoring of efficacy and local skin reaction. Int J Dermatol. 2018;57(10):1178–81.

    CAS  PubMed  Google Scholar 

  77. MacFarlane DF, El Tal AK. Cryoimmunotherapy: superficial basal cell cancer and squamous cell carcinoma in situ treated with liquid nitrogen followed by imiquimod. Arch Dermatol. 2011;147(11):1326–7.

    PubMed  Google Scholar 

  78. Vale SM, Hill D, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis: an update. Pharmacoeconomics. 2017;10(10):28–33.

    Google Scholar 

  79. Imiquimod [package insert]. Bristol, TN: Bristol Pharmaceuticals, LLC; 2010.

    Google Scholar 

  80. Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol Surg. 2013;39(9):1306–16.

    CAS  PubMed  Google Scholar 

  81. Collins A, Savas J, Doerfler L. Nonsurgical treatments for nonmelanoma skin cancer. Dermatol Clin. 2019;37(4):435–41.

    CAS  PubMed  Google Scholar 

  82. Ezughah FI, Dawe RS, Ibbotson SH, et al. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolog Treat. 2008;19:111–7.

    CAS  PubMed  Google Scholar 

  83. Geisse J, Caro I, Lindholm K, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–33.

    PubMed  Google Scholar 

  84. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6- week dose–response trial. J Am Acad Dermatol. 2001;44:807–13.

    CAS  PubMed  Google Scholar 

  85. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007;6:507–13.

    PubMed  Google Scholar 

  86. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47.

    CAS  PubMed  Google Scholar 

  87. Alessi SS, Sanches JA, Oliveira WR, et al. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo). 2009;64:961–6.

    PubMed  Google Scholar 

  88. Warshauer E, Warshauer BL. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol. 2008;7(5):447–51.

    PubMed  Google Scholar 

  89. Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen’s disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55(2):324–7.

    PubMed  Google Scholar 

  90. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227–36.

    CAS  PubMed  Google Scholar 

  91. Ruiz-Villaverde R, Sanchez-Cano D, Burkhardt-Perez P. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol. 2009;23:828–31.

    CAS  PubMed  Google Scholar 

  92. Quirk C, Gebauer K, De’Ambrosis B, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85:318–24.

    PubMed  Google Scholar 

  93. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677–82.

    CAS  PubMed  Google Scholar 

  94. Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol. 2006;47:169–71.

    PubMed  Google Scholar 

  95. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616–21.

    PubMed  Google Scholar 

  96. Huber A, Huber JD, Skinner RB, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open label series. Dermatol Surg. 2004;30:429–30.

    PubMed  Google Scholar 

  97. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol. 2002;138:1165–71.

    CAS  PubMed  Google Scholar 

  98. Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462–9.

    PubMed  Google Scholar 

  99. Gross K, Kircik L. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433–9.

    CAS  PubMed  Google Scholar 

  100. Smitha P, Raghavendra R, Sripathi H, et al. Successful use of imiquimod 5% cream in Bowen’s disease. Indian J Dermatol Venereol Leprol. 2007;73(6):423–5.

    Google Scholar 

  101. Love WE, Bernhard JD, Bordeux JS. Topical imiqui-mod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;15:1431–8.

    Google Scholar 

  102. Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized con- trol phase IIa trial. Australas J Dermatol. 2010;51:99–105.

    PubMed  Google Scholar 

  103. Brinkhuizen T, Frencken KJ, Nelemans PJ, et al. The effect of topical diclofenac 3% and calcitriol 3 mg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. J Am Acad Dermatol. 2016;75(1):126–34.

    CAS  PubMed  Google Scholar 

  104. Dika E, Fanti PA, Lambertini M, et al. Cutaneous squamous cell carcinoma progression during imiquimod treatment. J Am Acad Dermatol. 2018;79(1):e11–2.

    PubMed  Google Scholar 

  105. “5-fluorouracil” www.drugs.com, last updated June, 29, 2020.

  106. Drew BA, Karia PS, Liang CA, et al. Treatment patterns, outcomes, and patient satisfaction of primary epidermally limited nonmelanoma skin cancer. Dermatol Surg. 2017;43(12):1423–30.

    CAS  PubMed  Google Scholar 

  107. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–61.

    PubMed  Google Scholar 

  108. Dawe SA, Salisbury JR, Higgins E. Two cases of Bowen’s disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel. Clin Exp Dermatol. 2005;30:712–3.

    CAS  PubMed  Google Scholar 

  109. Patel MJ, Stockfleth E. Does progression from actinic keratosis and Bowen’s disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol. 2007;156(Suppl 3):53–6.

    CAS  PubMed  Google Scholar 

  110. Ondo AL, Mings SM, Pestak RM, et al. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006;55(6):1092–4.

    PubMed  Google Scholar 

  111. Thissen MR, Kuijpers DI, Krekis GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461–4.

    CAS  PubMed  Google Scholar 

  112. Costrales-Alvarez C, et al. Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication. Arch Soc Esp Oftalmol. 2017;92(2):93–6.

    Google Scholar 

  113. Salasche SJ. Curettage and electrodessication in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol. 1983;8:496–503.

    CAS  PubMed  Google Scholar 

  114. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas, part 4: x-ray therapy. J Dermatol Surg Oncol. 1992;18:549–54.

    CAS  PubMed  Google Scholar 

  115. Suhge d’Aubermont PC, Bennett RG. Failure of curettage and electrodessication for removal of basal cell carcinoma. Arch Dermatol. 1984;120:1456–60.

    PubMed  Google Scholar 

  116. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodessication for basal cell carcinoma: preliminary report. J Drugs Dermatol. 2008;7(Suppl 1):15–6.

    Google Scholar 

  117. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007;6(9):910–4.

    PubMed  Google Scholar 

  118. Nelson CG, Spencer J, Nelson CG Jr. A single-arm, open label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol. 2007;6(7):712–7.

    PubMed  Google Scholar 

  119. Ulrich C, Forschner T, Ulrich M, et al. Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol. 2007;156(Suppl 3):43–6.

    CAS  PubMed  Google Scholar 

  120. Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol. 1977;113:906–8.

    CAS  PubMed  Google Scholar 

  121. Smith KJ, Germain M, Yeager J, et al. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol. 2002;47(4):497–501.

    PubMed  Google Scholar 

  122. Huseion-ElAhmed H, Almazan-Fernandez FM, Huseion-ElAhmed S. Ingenol mebutate versus imiquimod versus diclofenac for actinic cheilitis: a 6-month follow-up clinical study. Clin Exp Dermatol. 2018;44(2):231–4.

    Google Scholar 

  123. Biasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol. 2005;140(6):1136–9.

    Google Scholar 

  124. Choontanom R, Thanos S, Busse H, et al. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1217–20.

    CAS  PubMed  Google Scholar 

  125. Leppala J, Kaarniranta K, Uuusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85(5):566–8.

    PubMed  Google Scholar 

  126. Galentine P, Sloas H, Hargett N, et al. Bilateral cicatricial ectropion following topical administration of 5-fluorouracil. Ann Ophthalmol. 1981;13(5):575–7.

    CAS  PubMed  Google Scholar 

  127. Hecker D, Hacker SM, Ramos-Caro FA, et al. Temporary ectropion due to topical fluorouracil. Cutis. 1994;53(3):137–8.

    CAS  PubMed  Google Scholar 

  128. Lewis JE. Temporary ectropion due to topical fluorouracil. Int J Dermatol. 1997;36(1):79.

    CAS  PubMed  Google Scholar 

  129. Poothullil AM, Colby KA. Topical medical therapies for ocular surface tumors. Semin Ophthalmol. 2006;21(3):161–9.

    PubMed  Google Scholar 

  130. Danielsen AG, Sand C, Weisman K. Treatment of Bowen’s disease of the penis with imiquimod 5% cream. Clin Exp Dermatol. 2003;28(Suppl 1):7–9.

    PubMed  Google Scholar 

  131. Micali G, Nasca MR, Tedeschi A. Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin Exp Dermatol. 2003;28(Suppl 1):4–6.

    PubMed  Google Scholar 

  132. Orengo I, Rosen T, Guill C. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol. 2002;47(4):225–8.

    Google Scholar 

  133. Goorney BP, Polori R. A case of bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. Int J STD AIDS. 2004;15(12):833–5.

    CAS  PubMed  Google Scholar 

  134. Bernstein DI, Spruance SL, Arora SS, et al. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis. 2005;41(6):808–14.

    CAS  PubMed  Google Scholar 

  135. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002;46(4):545–8.

    PubMed  Google Scholar 

  136. Ferreres JR, Macaya A, Jucgla A, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2006;20(7):877–8.

    CAS  PubMed  Google Scholar 

  137. Micali G, Lacarrubba F, Nasca MR, et al. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003;28(Suppl 1):19–23.

    PubMed  Google Scholar 

  138. Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569–72.

    PubMed  Google Scholar 

  139. Vereecken P, Monsieur E, Petein M, et al. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat. 2004;15(2):120–1.

    CAS  PubMed  Google Scholar 

  140. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  141. Geissler EK. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res. 2015;4:1.

    PubMed  PubMed Central  Google Scholar 

  142. Werner RN, Summain A, Erdmann R, et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.

    CAS  PubMed  Google Scholar 

  143. Heppt MV, Steeb T, Niesert AC, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180:43–50.

    CAS  PubMed  Google Scholar 

  144. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27(6):561–4.

    CAS  PubMed  Google Scholar 

  145. Torres A, Marra D, Desai TD, et al. Imiquimod 5% cream does not induce tumor skip areas in the topical treatment of basal cell carcinoma. Unpublished data.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mohs Micrographic Surgery and Dermatologic Oncology, University of North Texas Health Sciences, Ft. Worth, TX, USA

    Richard R. Winkelmann

  2. Dermatology and Dermatologic Surgery, University of North Texas Health Sciences, Ft. Worth, TX, USA

    Tejas D. Desai

  3. Mohs Micrographic Surgery and Dermatologic Oncology, University of Florida College of Medicine, Gainesville, FL, USA

    Maheera Farsi

  4. University of Florida, Shands Hospital, Department of Dermatology, Gainesville, FL, USA

    Abel Torres

Authors
  1. Richard R. Winkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tejas D. Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maheera Farsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abel Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Deborah F. MacFarlane

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Winkelmann, R.R., Desai, T.D., Farsi, M., Torres, A. (2021). Topical Therapies for Nonmelanoma Skin Cancers. In: MacFarlane, D.F. (eds) Skin Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-030-50593-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-50593-6_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-50592-9

  • Online ISBN: 978-3-030-50593-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation